Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study
Objective: Elevated lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and has no approved pharmacotherapies. Limited real-world data exists on the proportion of patients with available Lp(a) test results, characteristics of these patients, and their use of li...
Saved in:
Main Authors: | Xingdi Hu (Author), Joaquim Cristino (Author), Raju Gautam (Author), Rina Mehta (Author), Diana Amari (Author), Ji Haeng Heo (Author), Siwei Wang (Author), Nathan D. Wong (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
by: Bożena Sosnowska, et al.
Published: (2022) -
Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review
by: Jakub Michal Zimodro, et al.
Published: (2024) -
Sex differences in lipid and lipoprotein metabolism
by: Brian T. Palmisano, et al.
Published: (2018) -
Lipid and lipoprotein concentrations during pregnancy and associations with ethnicity
by: Christin W. Waage, et al.
Published: (2022) -
Serum lipid, lipoprotein and oxidatively modified low density lipoprotein levels in active or inactive patients with behçet's disease
by: Fuat Cimen, et al.
Published: (2012)